Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Minerva Neurosciences, Inc.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics, Inc.

Minerva Neurosciences focuses on clinical development in central nervous system disorders, designing innovative trials aimed at patient benefit.

Metric
Company Name	Minerva Neurosciences, Inc.	Axsome Therapeutics, Inc.
Symbol	NERV	AXSM
MSH ID	COM:MINERVANEUROSCIENCES	COM:AXSOME
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology
Country	US	US
Stage		Post-IPO Equity
Employee Count	9	569
Website	minervaneurosciences.com	axsome.com
LinkedIn
Founders

Metric
Market Cap	23.43M	3.92B
Enterprise Value
Monthly Web Traffic		7.82K
Web Traffic Growth		-0.74
Valuation
Raised Capital		225M

Metric
Revenue		270.60M
Revenue (LTM)
Revenue (NTM)
Gross Profit		237.70M
EBITDA		-176.07M
Operating Income		-182.91M
Net Income		-239.24M
EPS		-5.27
Diluted EPS		-5.27
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.90
Operating Profit Margin		-0.86
EBITDA Margin		-0.65
Net Profit Margin		-0.88
Return on Equity		-1.12
Return on Assets		-0.41
Return on Capital Employed		-0.52

COM:MINERVANEUROSCIENCES

Minerva Neurosciences

Last Close

2.16

22/11 21:00

Market Cap

23.43M

Beta: -

Volume Today

6.46K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-20.81
P/B Ratio		16.01
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		16.65
EV Multiple		-11.57

Metric
Days Sales Outstanding		128.09
Days Payables Outstanding		506.28
Days Inventory Outstanding		229.29
Operating Cycle		383.54
Cash Conversion Cycle		-229.81
Asset Turnover		0.53

Metric
Operating Cash Flow		-145.08M
Free Cash Flow		-145.66M
Cash Flow to Debt		-0.81
Operating Cash Flow/Sales		-0.54
Free Cash Flow Yield		-0.03

Metric
Cash & Equivalents		386.19M
Accounts Receivable		-57.12M
Inventory		15.13M
Goodwill		12.04M
Debt to Capitalization		0.65
Debt to Assets		0.31
Current Ratio		4.46
Quick Ratio		3.46

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.24
R&D to Revenue		0.37
SG&A to Revenue		0.44